Management of Urinary Tract Infections in Primary Care Facilities.

Use of Standardized Delegation Form in Diagnosing and Treating Acute Cystitis in Primary Care Facilities.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01132131

Enrollment

443

Registered

2010-05-27

Start date

2010-08-31

Completion date

2011-12-31

Last updated

2012-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Tract Infection

Keywords

Urinary tract infection, Cystitis, Bacteruria

Brief summary

The Emergency Ward Center in Oslo has the last two years used a questionnaire to identify patients who qualify for treatment of acute cystitis by the use of a delegation form. The aim of the study is to evaluate this practice, the primary objective being to evaluate if in a selected patient group the treatment outcome after identifying patients with probable acute cystitis by delegation form will be as good or better than the treatment received after a regular doctor's consultation. The planned study will also investigate which symptoms, signs and laboratory findings that coincide with significant bacteruria. The reference standard will be a microbiological culture of every patients urine.

Interventions

OTHERDelegation form

The study aims to compare the use of a delegation form to identify patient's who qualify for antibiotic treatment for suspected acute cystitis with a regular doctor's consultation. The key outcomes are lack of bacteruria and symptoms of UTI at followup times.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

16 Years to 55 Years

Healthy volunteers

Inclusion criteria

* Females 16-55 years * Dysuria * Increased frequency of urination

Exclusion criteria

* Pregnant * Breastfeeding child \< 1 month of age * Diabetes * Kidney disease * Fever * Poor general condition * Backpain * Abdominal pain * Increased amount of vaginal secretions * Vaginal itching or pain * Urinary tract infection in the last four weeks * Use of urinary catheter in the last four weeks * Symptoms lasting more than seven days * Ongoing antibiotic treatment * Allergy to penicillin * Use of the medicine Probecid

Design outcomes

Primary

Measure	Time frame	Description
Number of patients who are clinically and bacteriologically free of symptoms of urinary tract infection.	6 days after start of treatment.	The antibiotic treatment given will be of three days length.
Number of patients who are clinically and symptomatologically free of symptoms.	10 days after start of treatment	The antibiotic treatment will be of three days length

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026